恢复期血浆疗法

预约门诊
打印

研究

妙佑医疗国际的研究人员正在研究采用恢复期血浆治疗 2019 新型冠状病毒肺炎住院患者。这项研究的近期目标是确定恢复期血浆疗法能否提高危重症患者康复的几率。第二个目标是确定恢复期血浆能否防止中度症状患者的病情加重。

查阅更多妙佑医疗国际有关 2019 新型冠状病毒肺炎研究的信息。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在恢复期血浆治疗领域的文献著述列表。

Research Profiles

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
April 28, 2021
打印
  1. Convalescent plasma COVID-19: EUA letter of authorization. U.S. Food and Drug Administration. https://www.fda.gov/media/141477/download. Accessed April 22, 2021.
  2. Joyner MJ, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three month experience. Preprint. medRxiv. 2020; doi:10.1101/2020.08.12.20169359.
  3. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed Aug. 24, 2020.
  4. Host modifiers and immune-based therapy under evaluation for treatment of COVID-19. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/. Accessed May 8, 2020.
  5. Donate COVID-19 plasma. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma. Accessed Aug. 24, 2020.
  6. Plasma donations from recovered COVID-19 patients. American Red Cross. https://www.redcrossblood.org/donate-blood/dlp/plasma-donations-from-recovered-covid-19-patients.html. Accessed May 8, 2020.
  7. Rajendran K, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. 2020; doi:10.1002/jmv.25961.
  8. Investigational COVID-19 convalescent plasma — Emergency INDs: Frequently asked questions. U.S. Food and Drug Administration. https://www.fda.gov/media/136470/download. Accessed May 8, 2020.
  9. Expanded access to convalescent plasma for the treatment of patients with COVID-19. https://www.uscovidplasma.org/. Accessed Aug. 24, 2020.
  10. Coronavirus disease 2019 (COVID-2019). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed May 8, 2020.
  11. Kim AR. Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. https://www.uptodate.com/contents/search. Accessed May 8, 2020.
  12. AskMayoExpert. COVID-19: Adult. Mayo Clinic; 2020.
  13. Joyner MJ (expert opinion). Mayo Clinic. May 8, 2020.
  14. Emergency use authorization. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. . Accessed April 22, 2021.
  15. Coronavirus disease 2019 (COVID-19) treatment guidelines: Convalescent plasma. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/convalescent-plasma/. Accessed April 22, 2021.
  16. Klassen SA, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: Systematic review and meta-analysis. Mayo Clinic Proceedings. 2021; doi:10.1016/j.mayocp.2021.02.008.
  17. Joyner MJ, et al. Convalescent plasma antibody levels and risk of death from COVID-19. The New England Journal of Medicine. 2021; doi:10.1056/NEJMoa2031893.

相关

产品与服务

恢复期血浆疗法